AU2017297402B2 - Encochleated antifungal compounds for central nervous system delivery and treatment of Cryptococcus infections - Google Patents

Encochleated antifungal compounds for central nervous system delivery and treatment of Cryptococcus infections Download PDF

Info

Publication number
AU2017297402B2
AU2017297402B2 AU2017297402A AU2017297402A AU2017297402B2 AU 2017297402 B2 AU2017297402 B2 AU 2017297402B2 AU 2017297402 A AU2017297402 A AU 2017297402A AU 2017297402 A AU2017297402 A AU 2017297402A AU 2017297402 B2 AU2017297402 B2 AU 2017297402B2
Authority
AU
Australia
Prior art keywords
antifungal
cochleate
days
flucytosine
cochleates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017297402A
Other languages
English (en)
Other versions
AU2017297402A1 (en
Inventor
Doug F. Kling
Ruying Lu
Raphael J. Mannino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matinas Biopharma Nanotechnologies Inc
Original Assignee
Matinas Biopharma Nanotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matinas Biopharma Nanotechnologies Inc filed Critical Matinas Biopharma Nanotechnologies Inc
Publication of AU2017297402A1 publication Critical patent/AU2017297402A1/en
Application granted granted Critical
Publication of AU2017297402B2 publication Critical patent/AU2017297402B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2017297402A 2016-07-12 2017-07-12 Encochleated antifungal compounds for central nervous system delivery and treatment of Cryptococcus infections Active AU2017297402B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662361351P 2016-07-12 2016-07-12
US62/361,351 2016-07-12
US201762513800P 2017-06-01 2017-06-01
US62/513,800 2017-06-01
PCT/US2017/041750 WO2018013711A1 (en) 2016-07-12 2017-07-12 Encochleated antifungal compounds for central nervous system delivery and treatment of cryptococcus infections

Publications (2)

Publication Number Publication Date
AU2017297402A1 AU2017297402A1 (en) 2019-01-03
AU2017297402B2 true AU2017297402B2 (en) 2023-02-09

Family

ID=60952715

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017297402A Active AU2017297402B2 (en) 2016-07-12 2017-07-12 Encochleated antifungal compounds for central nervous system delivery and treatment of Cryptococcus infections

Country Status (8)

Country Link
US (3) US11123295B2 (enExample)
EP (1) EP3484447A4 (enExample)
JP (1) JP6991592B2 (enExample)
KR (2) KR20190029642A (enExample)
CN (2) CN109689028A (enExample)
AU (1) AU2017297402B2 (enExample)
CA (1) CA3027668A1 (enExample)
WO (1) WO2018013711A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150297725A1 (en) 2012-07-30 2015-10-22 Rutgers, The State University Of New Jersey Cochleates made with soy phosphatidylserine
MX2022001871A (es) * 2019-08-13 2022-03-11 Matinas Biopharma Nanotechnologies Inc Metodos de tratamiento de las infecciones por criptococo.
CN118370831A (zh) * 2023-01-20 2024-07-23 中国科学院微生物研究所 肌醇磷脂酰胺合成酶抑制剂与两性霉素b的联合用药及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140220108A1 (en) * 2011-05-05 2014-08-07 University Of Medicine And Dentistry Of New Jersey Cochleate compositions and methods of making and using same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739591B2 (en) * 1996-08-09 2001-10-18 Buckman Laboratories International, Inc. Treatment of fungal infections using a combination of an anti-fungal compound and an N-alkyl heterocyclic compound
US5837254A (en) * 1996-11-14 1998-11-17 Chen; Yu Method of treating candida and cryptococcus fungal infections by administering gentian
US6153217A (en) 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
AUPQ066399A0 (en) * 1999-05-31 1999-06-24 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
JP2003529557A (ja) 2000-01-24 2003-10-07 バイオデリバリー サイエンス インコーポレーテッド コクリエート製剤、その調製方法および生物学的関連分子投与のための用途
US20030219473A1 (en) 2002-03-26 2003-11-27 Leila Zarif Cochleates made with purified soy phosphatidylserine
CA2504329C (en) 2002-11-01 2013-08-20 Biodelivery Sciences International, Inc. Geodate delivery vehicles
US20050013854A1 (en) * 2003-04-09 2005-01-20 Mannino Raphael J. Novel encochleation methods, cochleates and methods of use
WO2004092123A2 (en) 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
EP1812555B1 (en) * 2004-10-25 2015-04-22 Cellerant Therapeutics, Inc. Methods of expanding myeloid cell populations and uses thereof
RU2396955C2 (ru) * 2005-04-07 2010-08-20 Тояма Кемикал Ко., Лтд. Фармацевтическая комбинация и способ применения противогрибкового средства в комбинации
CA2613705A1 (en) * 2005-06-29 2007-01-04 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic pr0tein-lip1d complexes
WO2009006311A2 (en) * 2007-06-29 2009-01-08 Wisconsin Alumni Research Foundation Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
DE102008054431B3 (de) * 2008-12-09 2010-06-17 Pari Pharma Gmbh Aerosoltherapievorrichtung
WO2010091090A1 (en) * 2009-02-03 2010-08-12 Biodelivery Sciences International, Inc. Cochleate compositions and methods of use
US20150297725A1 (en) 2012-07-30 2015-10-22 Rutgers, The State University Of New Jersey Cochleates made with soy phosphatidylserine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140220108A1 (en) * 2011-05-05 2014-08-07 University Of Medicine And Dentistry Of New Jersey Cochleate compositions and methods of making and using same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Brizendine, K.D. et al., "Cryptococcal Meningitis: Current Approaches to Management in Patients With and Without AIDS", Current Infectious Disease Reports, 2010, vol. 12, no. 4, pages 299-305, DOI: 10.1007/s11908-010-0113-4 *
Perlin, D.S., "Amphotericin B cochleates: a vehicle for oral delivery", Current Opinion in Investigational Drugs, 2004, vol. 5, no. 2, pages 198-201, *
Rhein, J. et al., "Prognosis and management of cryptococcal meningitis in patients with human immunodeficiency virus infection", Neurobehavioral HIV Medicine, 2012, vol. 4, pages 45-61, DOI: 10.2147/NBHIV.S24748 *
Zarif, L., "Elongated supramolecular assemblies in drug delivery", Journal of Controlled Release, 2002, vol. 81, no. 1-2, pages 7-23, DOI: 10.1016/S0168-3659(02)00010-X *

Also Published As

Publication number Publication date
CA3027668A1 (en) 2018-01-18
EP3484447A4 (en) 2020-07-22
KR20190029642A (ko) 2019-03-20
CN109689028A (zh) 2019-04-26
KR20230003167A (ko) 2023-01-05
US11123295B2 (en) 2021-09-21
EP3484447A1 (en) 2019-05-22
WO2018013711A1 (en) 2018-01-18
US20240423916A1 (en) 2024-12-26
JP6991592B2 (ja) 2022-01-12
US20210393526A1 (en) 2021-12-23
JP2019520407A (ja) 2019-07-18
AU2017297402A1 (en) 2019-01-03
US20200121601A1 (en) 2020-04-23
CN114053417A (zh) 2022-02-18

Similar Documents

Publication Publication Date Title
US20240423916A1 (en) Encochleated antifungal compounds for central nervous system delivery and treatment of cryptococcus infections
JP5855829B2 (ja) リポソーム化バンコマイシン製剤
KR970007187B1 (ko) 개선된 암포테리신 b 리포좀 제조법
JP5920875B2 (ja) 真菌感染症を治療するための新規な製剤
WO2021202912A1 (en) Compositions for treatment of viral respiratory infections and methods of use thereof
WO2019213101A1 (en) Liposomal nano formulation of combinational antibiotics and the uses thereof
US9820940B2 (en) Liposomal formulations of polymyxin and uses thereof
JPH07501825A (ja) 高められた抗真菌活性を有するアンフォテリシンｂ組成物
US20220313717A1 (en) Methods of treating cryptococcus infections
US11273124B2 (en) Antifungal nanoparticles for targeted treatment of fungal infections
WO2024039729A1 (en) Antifungal agent encapsulated in a lipid nanocrystal for treating mucormycosis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)